Bevacizumab in the treatment of colorectal cancer

Jeffrey C. Cilley, Keren Barfi, Al B. Benson, Mary F. Mulcahy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Colorectal cancer is a common disease with therapy that has a proven effectiveness in the adjuvant and metastatic setting. Bevacizumab, a vascular endothelial growth factor inhibitor, is an antiangiogenesis monoclonal antibody that has benefit in response rate and overall survival when used in combination with existing metastatic colorectal cancer regimens. It is well tolerated with a few important side effects to be cognizant of, including hypertension, arterial thrombosis and bowel perforation. Existing treatment and research strategies are examining its use in the adjuvant setting or in combination with other angiogenesis inhibitors.

Original languageEnglish (US)
Pages (from-to)739-749
Number of pages11
JournalExpert Opinion on Biological Therapy
Issue number5
StatePublished - May 2007


  • Bevacizumab
  • Colorectal cancer
  • VEGF

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Pharmacology


Dive into the research topics of 'Bevacizumab in the treatment of colorectal cancer'. Together they form a unique fingerprint.

Cite this